Replies to post #173700 on Biotech Values

[DewDiligence]

MNK acquires CADX for $14/sh, a 26% premium to yesterday’s closing price:

http://finance.yahoo.com/news/mallinckrodt-plc-acquire-cadence-pharmaceuticals-120000298.html

CADX’s claim to fame is Ofirmev, an IV formulation of acetaminophen for hospital use. The nominal deal value is $1.3B. MNK was the 2013 pharma spin-off from COV, which was itself spun off from Tyco in 2007.

CC at 8:30am ET.